Amplia Therapeutics Limited (ASX: ATX) - Share Price
Current share price for ATX : $0.115 0.005 (4.17%)+
Amplia Therapeutics Limited (ATX), an ASX-listed company, is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a role in chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
ATX General Information +
| ASX Code | ATX |
| Website | http://www.ampliatx.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 59 |
| ATX Share Price | $0.115 |
| Day High | $0.120 |
| Day Low | $0.115 |
| Last Close | $0.120 |
| ATX Share Price Movement | $0.00 ( 4.17% ) |
Prices as at 16:35, 19 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Amplia Therapeutics Limited (ATX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Amplia Therapeutics Limited (ATX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Amplia Therapeutics Limited (ATX) price-sensitive announcements
ATX - Preliminary Final Report and Annual Report YE 31 March 2026
Amplia Therapeutics Limited's financial report for the year ending 31 March 2026, highligh
Amplia Therapeutics Limited (ATX)
29 May 2026 | 1:37 PM
29 May 2026 | 1:37 PM
ATX - Amplia Launches First Stage of Pivotal Narmafotinib Trial
Amplia Therapeutics Limited has announced the initiation of a Phase 2b clinical trial for
Amplia Therapeutics Limited (ATX)
19 May 2026 | 8:18 AM
19 May 2026 | 8:18 AM
ATX - Amplia and ANZGOG announce Ovarian Cancer Study
Amplia Therapeutics Limited, in collaboration with the Australia New Zealand Gynaecologica
Amplia Therapeutics Limited (ATX)
8 May 2026 | 8:29 AM
8 May 2026 | 8:29 AM
ATX - Quarterly Activities/Appendix 4C Cash Flow Report
Amplia Therapeutics Limited has made significant progress in developing narmafotinib, a FA
Amplia Therapeutics Limited (ATX)
28 Apr 2026 | 9:38 AM
28 Apr 2026 | 9:38 AM
Amplia Therapeutics Limited (ATX) Recent ASX Announcements
ATX Financial Summary
| Year to Mar | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$7.71 | -$1.60 | -23.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$6.57 | -$2.10 | -3.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$4.50 | -$2.20 | -28.00% | 0.00 | 0.00 | 0.00% | 0.0% |
ATX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Amplia Therapeutics Limited (ATX) | $56M | -0.2336 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $51,143M | 0.1108 | -0.1334 | 0.0165 | 11.4512 | 13.2143 | 12.9995 | 4.17% | 3.36% | 3.50% |
| Clinuvel Pharmaceuticals Limited (CUV) | $493M | 0.0287 | 0.0233 | 0.0942 | 13.6212 | 13.3116 | 12.1657 | 0.51% | 0.74% | 1.20% |
| Mesoblast Limited (MSB) | $2,557M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,802M | -1.3893 | 0.0000 | -0.1311 | 0.0000 | 264.9813 | 304.9569 | 0.00% | 0.00% | 0.00% |
ATX Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 1.56 | 0.00 |
| Market | 0.30 | 13.20 | 1.17 | 0.70 |
| Sector | 0.40 | 26.80 | 2.60 | 2.33 |
ATX Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Christopher John Burns | Chief Executive Officer, Managing Director | 4 May 2018 |
| Mr Andrew John Cooke | Company Secretary | 1 Jan 0001 |
| Dr Robert Peach | Non-Executive Director | 2 Sep 2015 |
| Ms Jane Catherine Bell | Non-Executive Director | 12 Apr 2021 |
| Dr Warwick Bonner Tong | Non-Executive Director, Non-Executive Chairman | 4 May 2018 |
Amplia Therapeutics Limited (ATX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Sep 2025 | BELL, Jane | Issued | Indirect Shares | 130,435 | $0.230 | $30,000.050 |
| 1 Sep 2025 | TONG, Warwick | Issued | Indirect Shares | 152,174 | $0.230 | $35,000.020 |
| 1 Sep 2025 | BURNS, Christopher | Issued | Direct Shares | 86,957 | $0.230 | $20,000.110 |
See all changes in directors' interest & trades for Amplia Therapeutics Limited (ATX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ATX Management
| Name | Position |
|---|---|
| Hamish George | Chief Financial Officer |
| Jason Lickliter | Chief Medical Officer |
ATX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Amplia Therapeutics Limited (ATX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 45,313,932 (9.31%) | Platinum Investment Management Limited |
| 36,144,321 (7.43%) | Acorn Capital Limited |
ATX Calendar of Events
| Date | Event |
|---|---|
| 28 May 2027 | Report (Annual) |
| 28 May 2027 | Report (Prelim) |
| 26 November 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
